Drugs /

cetuximab

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
cetuximab
Trade Name(s):
Erbitux
NCI Definition [1]:
A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for cetuximab

Cetuximab has been investigated in 94 clinical trials, of which 79 are open and 15 are closed. Of the trials investigating cetuximab, 1 is early phase 1 (1 open), 18 are phase 1 (16 open), 22 are phase 1/phase 2 (17 open), 36 are phase 2 (30 open), 4 are phase 2/phase 3 (3 open), 11 are phase 3 (11 open), and 2 are no phase specified (1 open).

BRAF V600E, CDKN2A Overexpression, and HPV Negative are the most frequent biomarker inclusion criteria for cetuximab clinical trials.

Head and neck squamous cell carcinoma, colorectal carcinoma, and oropharyngeal squamous cell carcinoma are the most common diseases being investigated in cetuximab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Cetuximab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Cetuximab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cetuximab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
imc c225, anti-egfr monoclonal antibody, monoclonal antibody c225, chimeric monoclonal antibody c225, c225, mab, 205923-56-4, cetuximab, mab c225, cetuximab, c225, imc, cetuximabum, c225, chimeric moab c225, 11460, c225 monoclonal antibody, 714692, cétuximab, imcc225, cetuximab (product), cetuximab [chemical/ingredient], immunoglobulin g 1 (human-mouse monoclonal c 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal c 225 kappa - chain, dimer, cetuximab (substance), anti-epidermal growth factor receptor monoclonal antibody, chimeric anti-egfr monoclonal antibody, moab c225, immunoglobulin g1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal c225 gamma1-chain), disulfide with human-mouse monoclonal c225 kappa-chain, dimer, 3610, imc-c225, cmab009, Erbitux
Drug Categories [2]:
Therapeutic antibodies
Drug Target(s) [2]:
EGFR
NCIT ID [1]:
C1723
SNOMED ID [1]:
C-7904F

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.